Open Access
Table 5
Calculated waiting periods from time of death to body transport and embalming meeting the 300 μSv dose criterion per post-mortem procedure, for the scenario of death immediately following radiopharmaceutical administration (worst case for radiation protection).
| Radiopharmaceutical | Administered activity (GBq) | Waiting period (from time of death) before transport (days) | Waiting period (from time of death) before embalming (days) |
|---|---|---|---|
| indium-111-pentetreotide | 6.7 | 8 | 11 |
| iodine-131 ionic: non-cancer | 0.8 | 0 | 1 |
| iodine-131 ionic: cancer | 1.5 3.7 5.6 |
0 11 16 |
8 19 24 |
| iodine-131-MIBG | 5.6 7.4 |
16 19 |
24 27 |
| iodine-131-Lipiocis® | 2.2 | 5 | 13 |
| samarium-153-EDTMP (Quadramet®) | 4 | 0 | 2 |
| holmium-166-microspheres | 12 | 1 | 2 |
| lutetium-177-DOTATATE | 7.4 | 0 | 5 |
| lutetium-177-PSMA | 7.4 | 0 | 4 |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.